New data put more non-inferior SPRING in dolutegravir's step
This article was originally published in Scrip
Executive Summary
The Shionogi-ViiV Healthcare HIV drug joint venture has released additional findings from the SPRING-2 Phase III study with dolutegravir that further strengthen the case for the HIV integrase inhibitor's non-inferiority to Merck & Co's marketed same class drug Isentress (raltegravir).